Neurology
-
Randomized Controlled Trial Clinical Trial
Experimental brush-evoked allodynia activates posterior parietal cortex.
To study the brain activation pattern of coexisting experimental ongoing pain and brush-evoked allodynia (pain evoked by innocuous brush) with the use of PET. ⋯ The specific activation of contralateral BA 5/7 indicates that this brain region is important to the processing of brush-evoked allodynia. The involvement of BA 5/7 in brush-evoked allodynia is claimed to reflect multisensory input to this region, its role in conscious pain perception, and its neuroplastic properties.
-
Randomized Controlled Trial Clinical Trial
Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain.
To evaluate the effectiveness and safety of bupropion sustained-release (SR) for the treatment of neuropathic pain. ⋯ This placebo-controlled crossover trial showed that bupropion SR (150-300 mg daily) was effective and well tolerated for the treatment of neuropathic pain.
-
Randomized Controlled Trial Clinical Trial
Cerebral hemorrhage after intra-arterial thrombolysis for ischemic stroke: the PROACT II trial.
To analyze the frequency, clinical characteristics, and predictors of symptomatic intracerebral hemorrhage (ICH) after intraarterial (IA) thrombolysis with recombinant pro-urokinase (r-proUK) in acute ischemic stroke. ⋯ Symptomatic ICH after IA thrombolysis with r-proUK for acute ischemic stroke occurs early after treatment and has high mortality. The risk of symptomatic ICH may be increased in patients with a blood glucose >200 mg/dL at stroke onset.
-
Randomized Controlled Trial Multicenter Study Clinical Trial
A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients.
Citicoline may reduce CNS ischemic injury by stabilizing cell membranes and reducing free radical generation. Previous safety and efficacy trials in patients who have had acute strokes suggested that citicoline may improve neurologic outcome with minimal side effects. ⋯ Citicoline was safe but ineffective in improving the outcome of patients with acute ischemic stroke as measured by the planned analyses. Post hoc analyses suggest that a modest treatment effect may have been seen if more traditional analyses had been used.